HAE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HAE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-28), Haemonetics's current share price is $90.99. Haemonetics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $1.77. Haemonetics's Cyclically Adjusted Price-to-FCF for today is 51.41.
The historical rank and industry rank for Haemonetics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Haemonetics's highest Cyclically Adjusted Price-to-FCF was 112.62. The lowest was 28.10. And the median was 46.03.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Haemonetics's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $-0.444. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.77 for the trailing ten years ended in Dec. 2023.
The historical data trend for Haemonetics's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 48.68 | 47.61 | 47.98 | 47.17 | 48.21 |
For the Medical Instruments & Supplies subindustry, Haemonetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Haemonetics's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Haemonetics's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 90.99 | / | 1.77 | |
= | 51.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Haemonetics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -0.444 | / | 129.4194 | * | 129.4194 | |
= | -0.444 |
Current CPI (Dec. 2023) = 129.4194.
Haemonetics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | 0.410 | 99.695 | 0.532 |
201406 | -0.451 | 100.560 | -0.580 |
201409 | -0.049 | 100.428 | -0.063 |
201412 | -0.053 | 99.070 | -0.069 |
201503 | 0.643 | 99.621 | 0.835 |
201506 | -0.292 | 100.684 | -0.375 |
201509 | 0.032 | 100.392 | 0.041 |
201512 | 0.160 | 99.792 | 0.208 |
201603 | 0.486 | 100.470 | 0.626 |
201606 | 0.161 | 101.688 | 0.205 |
201609 | 0.389 | 101.861 | 0.494 |
201612 | 0.697 | 101.863 | 0.886 |
201703 | 0.365 | 102.862 | 0.459 |
201706 | 0.468 | 103.349 | 0.586 |
201709 | 0.821 | 104.136 | 1.020 |
201712 | 0.731 | 104.011 | 0.910 |
201803 | 0.711 | 105.290 | 0.874 |
201806 | -0.084 | 106.317 | -0.102 |
201809 | 0.167 | 106.507 | 0.203 |
201812 | 0.548 | 105.998 | 0.669 |
201903 | 0.133 | 107.251 | 0.160 |
201906 | -0.110 | 108.070 | -0.132 |
201909 | 0.392 | 108.329 | 0.468 |
201912 | 1.140 | 108.420 | 1.361 |
202003 | 0.697 | 108.902 | 0.828 |
202006 | 0.080 | 108.767 | 0.095 |
202009 | 0.407 | 109.815 | 0.480 |
202012 | 1.108 | 109.897 | 1.305 |
202103 | -0.196 | 111.754 | -0.227 |
202106 | -0.306 | 114.631 | -0.345 |
202109 | 0.440 | 115.734 | 0.492 |
202112 | 0.697 | 117.630 | 0.767 |
202203 | 0.641 | 121.301 | 0.684 |
202206 | -0.067 | 125.017 | -0.069 |
202209 | 0.991 | 125.227 | 1.024 |
202212 | 0.929 | 125.222 | 0.960 |
202303 | 1.322 | 127.348 | 1.344 |
202306 | 0.184 | 128.729 | 0.185 |
202309 | 1.449 | 129.860 | 1.444 |
202312 | -0.444 | 129.419 | -0.444 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Haemonetics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Stewart W Strong | officer: President, Global Hospital | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Anila Lingamneni | officer: EVP, Chief Technology Officer | HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Charles J Dockendorff | director | COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
Diane M Bryant | director | 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054 |
Josep Llorens | officer: EVP, Global Manufacturing | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Michelle L Basil | officer: EVP and General Counsel | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Farris Maryanne Maunsell | officer: VP, Chief Accounting Officer | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Roy Galvin | officer: President, Global Plasma & BC | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Laurie A. Miller | officer: SVP, Human Resources | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Mark W Kroll | director | PO BOX 23, CRYSTAL BAY MN 55323 |
Dan Goldstein | officer: VP, Corporate Controller | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Christopher Simon, | director, officer: President & CEO | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
James Darecca | officer: EVP, Chief Financial Officer | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Burke William P. Mr. | officer: EVP, Chief Financial Officer | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Lloyd Emerson Johnson | director | 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277 |
From GuruFocus
By PRNewswire PRNewswire • 08-10-2022
By PRNewswire PRNewswire • 12-19-2022
By PRNewswire PRNewswire • 04-25-2023
By PRNewswire PRNewswire • 07-09-2022
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire PRNewswire • 08-29-2022
By PRNewswire PRNewswire • 11-07-2022
By PRNewswire PRNewswire • 07-14-2022
By PRNewswire PRNewswire • 08-23-2022
By PRNewswire • 10-10-2023